Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT05460598
Other study ID # 2022-00160; th21Mueller2
Secondary ID
Status Active, not recruiting
Phase N/A
First received
Last updated
Start date August 1, 2022
Est. completion date June 2024

Study information

Verified date February 2024
Source University Hospital, Basel, Switzerland
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This single-blinded (only patients blinded) study is to assess the effect of cooling beddings on itch. The primary objective is to test whether or not the use of the cooling beddings during 3 days can add at least 20% improvement in (nocturnal) itch as measured by the 0-10 NRS in comparison to a control group that does not use the cooling beddings.


Description:

Itch is the most common skin-related symptom. Staying/sleeping in a bed with a cooling properties could have a positive effect on (nocturnal) itch intensity, sleep quality and daytime performance in consequence. A mattress topper and bed linen with cooling effects that are commercially available (https://www.oba.ch/cool_gel_topper) by the OBA AG (Basel), which is the supplier of beds and bedding items of the University Hospital Basel, has been used in clinical routine. This single-blinded (only patients blinded) study is to assess the effect of cooling beddings on itch and to better rationalize the beddings 'use. No comparative data is available and the design is purely exploratory. The primary objective of this study is to test whether or not the use of the cooling beddings during 3 days can add at least 20% improvement in (nocturnal) itch as measured by the 0-10 NRS in comparison to a control group that does not use the cooling beddings.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 15
Est. completion date June 2024
Est. primary completion date September 30, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Mean itch intensity NRS > 5 in the past 3 days - Literacy and ability to read - Inpatient stay required for > 3 nights Exclusion Criteria: - Age < 18 years - Illiteracy - Cognitive impairment (exclusion in case of mild cognitive impairment according to the Montreal-Cognitive Assessment (MOCA)) - The duration of the hospitalisation is foreseen to be shorter than 3 days - Para- and Tetraplegia - Hemisensory syndrome - Core body temperature >38°C - Use of other bedding > 8 hours or 2nd time request - Use of an occlusive therapy

Study Design


Related Conditions & MeSH terms


Intervention

Other:
beddings with cooling effects
beddings with cooling effects (mattress topper and bed linen)
commonly used bedding
commonly used bedding

Locations

Country Name City State
Switzerland Department of Dermatology, University Hospital Basel Basel

Sponsors (1)

Lead Sponsor Collaborator
University Hospital, Basel, Switzerland

Country where clinical trial is conducted

Switzerland, 

Outcome

Type Measure Description Time frame Safety issue
Primary improvement in (nocturnal) itch improvement in (nocturnal) itch as measured by the 0-10 Numeric rating Scale (NRS) (at least 2 NRS points per 24 hours to obtain a meaningful therapeutic benefit). (NRS, 0= no itch, 10= worst imaginable) NRS ratings will be assessed every 6 hours (throughout 72 hours)
Secondary Scratching activity measured by actigraph (Actigraph qGT3X-BT) on the dominant wrist Comparison of the actigraphy of the interventional versus control group.to record hand movements as a surrogate marker for scratching activity and to record sleep tracking functions. Continuously recorded throughout 72 hours
Secondary Richards-Campbell-Sleep Questionnaire (RCSQ) after each of the three nights addressing the sleep quality Sleep quality assessment by RCSQ. It consists of six items addressing "Sleep depth", "Sleep latency", "Awakenings", "Returning to sleep", "Sleep quality" and "Noise", each of which is rated on a visual analogue scales ranging from 0-100 mm. A higher value of the average score represents better sleep. Assessment after each night (3 times, altogether 72 hours)
Secondary Patient questionnaire (regarding lying comfort, cooling pleasantness) Patient questionnaire regarding lying comfort, cooling pleasantness (5-point Likert scales, items "Strongly disagree", "Disagree", "Neither agree nor disagree", "Agree" and "Strongly agree") One time assessment after the third night
Secondary Patient questionnaire regarding cooling intensity Patient questionnaire regarding cooling intensity (0-10/ no cooling- strongest-possible cooling). One time assessment after the third night
Secondary Staff questionnaire regarding time practicability Staff questionnaire regarding time practicability (putting on/of the linen, weight of topper, cleaning procedure of cooling beddings) (5-point Likert scales: "Strongly disagree", "Disagree", "Neither agree nor disagree", "Agree" and "Strongly agree") after their shift. Assessment after staff shift (3 times, altogether 72 hours)
Secondary Vital signs measured by Fitbit tracker On the non-dominant wrist, patients will wear a tracker (Fitbit Charge 5, Fitbit LLC, USA) to capture vital signs (e.g. heart rate, respiratory rate and skin temperature). Continuously recorded throughout 72 hours
See also
  Status Clinical Trial Phase
Completed NCT01683552 - Aprepitant in the Management of Biological Therapies-related Severe Pruritus Phase 2
Completed NCT02075632 - Study to Evaluate Product Duration of Use Experience With Alclometasone Dipropionate Cream Phase 2
Completed NCT04515056 - Characterization of New Human Models of Non-histaminergic Itch N/A
Completed NCT04076865 - Evaluation of the Effect Induced by Repeated Administration of Topical Local Anaesthetic (EMLA) on Itch N/A
Completed NCT04588532 - Characterization of BAM8-22 as a New Surrogate Model of Non-histaminergic Itch N/A
Enrolling by invitation NCT05195177 - Testing Protocol to Efficiently Induce Itch N/A
Withdrawn NCT03943407 - Characterization of the Toll-like Receptor 7-agonist Imiquimod 3.75% as a New Surrogate Model of Itch N/A
Completed NCT04858360 - Inhibition of Non-histaminergic Pruritus Applied Using 3 Different Pruritogens N/A
Completed NCT04635254 - The Effect of Halophyte-based Cream on Pain and Itch N/A
Not yet recruiting NCT06201715 - Efficacy and Safety of Tofacitinib in Patients With Prurigo Nodularis N/A
Completed NCT06036589 - Characterization of Bovine Adrenal Medulla as a Model of Non-histaminergic Itch N/A
Completed NCT04554888 - Characterization of New Human Models of Non-histaminergic Itch and Their Interaction With the TRPM8 Receptor N/A
Completed NCT04387851 - Learning Mechanisms for Placebo and Nocebo Studies on Somatosensory Sensations: a Systematic Review and Meta-analysis.
Completed NCT03928223 - The Color of Itch; Itch Modification by Color Viewing
Not yet recruiting NCT06245564 - Effect of Ketamine, Amitriptyline and Their Combination on Histaminergic and Non-histaminergic Itch N/A
Completed NCT03576053 - A Mechanistic Evaluation of the Interactions Between Thermoceptive and Pruriceptive Sensory Processing N/A
Completed NCT04700007 - Evaluation of Peripheral Itch Mechanisms Following Injection of Morphine (Second Sub-Project) N/A
Terminated NCT02828787 - Central Mechanisms of Chronic Pruritus: Functional and Structural Brain Imaging. N/A
Not yet recruiting NCT04197440 - Characterization of Bovine Adrenal Medulla (BAM8-22) as a New Surrogate Model of Non-histaminergic Itch N/A
Completed NCT04115462 - A Relation of Morphine-induced Itch and Pain Processing N/A